IDEXX Laboratories, Inc. — Q1 2022 Form 10-Q Summary
Business context and reporting period
IDEXX develops diagnostic products, veterinary laboratory and information-management services, water-testing products, livestock and poultry diagnostics, and selected human medical diagnostics. This unaudited Form 10-Q covers the three months ended March 31, 2022, compared with the three months ended March 31, 2021.
Reportable segments were Companion Animal Group (CAG), Water, Livestock, Poultry and Dairy (LPD), and Other. CAG represented approximately 91% of consolidated revenue.
Financial performance and key metrics
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Total revenue | $836.5 million | $777.7 million | Up 7.6% |
| Gross profit | $498.8 million | $470.8 million | Up 5.9% |
| Gross margin | 59.6% | 60.5% | Down 90 bps |
| Income from operations | $248.3 million | $247.6 million | Up 0.3% |
| Operating margin | 29.7% | 31.8% | Down 210 bps |
| Net income attributable to IDEXX stockholders | $194.0 million | $204.3 million | Down 5.0% |
| Diluted EPS | $2.27 | $2.35 | Down 3.4% |
| Operating cash flow | $114.7 million | $124.4 million | Down $9.7 million |
Reported revenue growth was reduced by a 1.9% currency headwind and increased by a 1.4% acquisition contribution; organic revenue growth was 8.0%. Product revenue increased to $478.4 million and service revenue increased to $358.2 million.
- CAG: Revenue increased 9.9% to $761.2 million, including 10.2% organic growth. CAG operating income increased 4.7% to $223.1 million, while margin declined to 29.3% from 30.8%.
- Water: Revenue increased 6.8% to $36.4 million and operating income increased 12.7% to $16.7 million.
- LPD: Revenue declined 21.4% to $30.9 million and operating income declined 51.2% to $6.7 million, primarily due to lower China swine-testing demand.
- Other: Revenue declined 30.1% to $8.1 million, principally due to lower COVID-19 testing activity and related consumables.
Liquidity, debt, and capital allocation
- Cash and cash equivalents were $204.6 million at March 31, 2022, compared with $144.5 million at December 31, 2021.
- Working capital was $118.4 million, down from $192.1 million at year-end 2021.
- The $1.0 billion revolving credit facility had $400.0 million outstanding, $598.6 million of remaining borrowing availability, and a weighted average effective interest rate of 1.2%.
- Long-term debt, net of current portion, was $773.4 million. The company repaid its $75.0 million 2022 Series A Senior Notes in February 2022.
- Gross debt was $1.185 billion, with gross debt to Adjusted EBITDA of 1.09x and net debt to Adjusted EBITDA of 0.90x. The company was in compliance with its 3.5x leverage covenant.
- Capital expenditures were $31.8 million in the quarter; management expected approximately $180.0 million of full-year 2022 capital spending.
- The company repurchased 502,411 shares under its repurchase program for $262.8 million and acquired an additional 20,449 shares through employee tax-withholding surrenders.
Material changes versus the prior comparable period
- Revenue growth remained strong, driven by CAG recurring diagnostics, instrument placements, software and services, pricing, and Water testing volumes.
- Profitability weakened despite higher revenue. Gross margin declined 90 basis points and operating margin declined 210 basis points due to product mix, higher product and service costs, freight and distribution costs, personnel investments, and other operating expenses.
- Net income declined primarily because the effective tax rate increased to 19.7% from 14.9%, largely reflecting lower share-based compensation tax benefits.
- Operating cash flow declined as higher inventory investment and other working-capital requirements offset improved accounts-receivable cash flow.
- Debt funding increased materially through $326.5 million of net revolving-credit borrowings, partly funding share repurchases and the repayment of senior notes.
- The company paid $10.0 million for a fully paid-up perpetual intellectual-property license during the quarter.
Guidance, outlook, commentary, risks, and unusual items
- Management expected supply-chain, logistics, inflationary, and product/component availability challenges to continue through 2022, although it believed mitigation efforts were maintaining product availability and customer service.
- Management expected LPD year-over-year comparisons to improve in the second half of 2022 as the prior-year impact of African Swine Fever programs and China-related conditions moderated.
- IDEXX significantly scaled back Russian operations, including suspending sales of veterinary diagnostic equipment. Revenue from Russia, Belarus, and Ukraine was approximately $10 million in 2021, and management expected regional revenue to be significantly limited during the remainder of 2022.
- Management projected that, for the remainder of 2022, a stronger U.S. dollar would reduce revenue by approximately $77 million, operating profit by approximately $16 million, and diluted EPS by approximately $0.14, partly offset by approximately $22 million of operating-profit benefit from hedging.
- In the second quarter, the company entered two intellectual-property arrangements involving $75.0 million of payments, expected milestone payments of $30.0 million, and an estimated aggregate research-and-development charge of approximately $80.0 million.
- An ongoing royalty litigation matter involves an approximately $50 million claim. The company had accrued $27.5 million, believes the claim is without merit, and is appealing an adverse trial-court ruling. The ultimate outcome remains uncertain.
- Revenue and asset balances include significant customer-program estimates, including approximately $157.0 million of capitalized customer acquisition costs and $172.6 million of net contract assets at March 31, 2022. Differences between estimated and actual customer purchases could affect revenue timing and asset realizability.
- The filing identifies the COVID-19 pandemic, the Ukraine war, supply-chain disruption, foreign-exchange volatility, inflation, cybersecurity, market conditions, and potential litigation or intellectual-property claims as material risks.
Most important facts for investors to verify
- Whether CAG recurring revenue growth and veterinary demand remain durable as clinical-visit growth normalizes after the pandemic-related surge.
- Whether gross and operating margins recover from Q1 pressure caused by mix, inflation, freight, distribution, and personnel investments.
- The pace of LPD recovery, particularly in China, and the continuing decline in Other-segment COVID-19 revenue.
- The effect of foreign-exchange movements, supply-chain constraints, inflation, and the Ukraine-related business suspension on full-year results.
- The timing and approximately $80 million impact of the second-quarter intellectual-property arrangements.
- Debt repayment, share repurchase levels, available revolver capacity, and compliance with the 3.5x leverage covenant.
- The ultimate outcome and potential exposure from the royalty litigation, including whether the $27.5 million accrual is sufficient.